About Prevencio
Prevencio is a Healthcare company based in Kirkland (United States) founded in 2006. Protein-based diagnostics and prognostics for cardiovascular diseases are developed. Prevencio has raised $5.68 million across 2 funding rounds. Prevencio offers products and services including HART Tests. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, In-Vitro Diagnostics and Diversified. Its legal entity is Prevencio Inc. Its competitors include SpectraWAVE, Proxim Diagnostics and Boston Heart Diagnostics; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2006 in Kirkland, United States, Prevencio operates in the biotechnology sector focused on cardiovascular health. Protein-based diagnostics and prognostic solutions are developed for diseases such as coronary artery disease. The HART assay, utilizing proteomics, is employed to diagnose coronary artery disease. Risks of myocardial infarction, stroke, or cardiovascular death within one year are assessed for diagnosed patients through protein signatures.
- Total Equity Funding$5.68M (USD)
in 2 rounds
- Latest Funding Round$675K (USD), Series B
Apr 2016
Products & Services of Prevencio
Prevencio offers a comprehensive portfolio of products and services, including HART Tests.
AI-powered blood tests for detecting heart disease and predicting risks.
Apps and channels of Prevencio
its YouTube channel Prevencio has 50 subscribers and 30 videos.
Videos from Prevencio
The most watched videos on Prevencio's YouTube channel, Prevencio (50 subscribers). Click a video to play it here.
More on Prevencio.
Funding Insights of Prevencio
Prevencio has successfully raised a total of $5.68M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $675 thousand completed in April 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.68M
- Total Rounds 2
- Last Round Series B — $675,000
- First Round $5M
(Jun 2015)
All 2 funding rounds of Prevencio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2016 | $675,000 | Series B | – | – | – |
| Jun 2015 | $5M | Series B | – | – | – |
People of Prevencio
11 people are tracked at Prevencio (7 in leadership, 3 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Celine Peters | COO | Leadership |
Aparna Rao | Director, Sales & Clinical Market Development | Leadership |
Michele McCarthy | CFO | Leadership |
Craig A. Magaret | Chief Analytics Officer | Leadership |
Rhonda F. Rhyne | CEO, President & Director | Leadership |
Caitlyn Dzhafarov | VP, Quality & Regulatory | Leadership |
Missy Martin-Kemp | Chief Commercial Officer | Leadership |
James L. Januzzi | Principal Investigator & Chair, Scientific & Clinical Advisory Board | Board & advisors |
Mark Houston | Scientific & Clinical Advisor | Board & advisors |
John F. Cramer III | Director | Board & advisors |
Katherine Kass | CCO, Functional & Concierge Medicine | Team |
Complete people profiles for Prevencio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Prevencio
3 dated milestones of Prevencio across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Prevencio is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Series B, of $675K.
Competitors of Prevencio
Prevencio has 3 listed competitors in our database, 3 of them funded. They include SpectraWAVE, Proxim Diagnostics and Boston Heart Diagnostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| spectrawave.com | 2012 | Waltham, United States | $79.88M | 36 | Photonic imaging diagnostics for cardiovascular disease treatment are provided. | |
| proximdx.com | 2010 | Sunnyvale, United States | $22.9M | Handheld immunodiagnostic devices for cardiac vascular diseases are developed. | ||
| bostonheartdiagnostics.com | 2007 | Framingham, United States | $10.34M | Diagnostics for personalized cardiovascular disease management are developed. |
Detailed competitors of Prevencio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Prevencio
The website of Prevencio (prevenciomed.com) receives about 1.7K visits a month.
- Monthly visits1.7K
▲ 23.2% vs previous month
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Prevencio (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Prevencio
Complete news archive for Prevencio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prevencio
Prevencio was founded in 2006 and raised its 1st funding round 9 years after it was founded.
Prevencio is headquartered in Kirkland, United States. It is registered at Kirkland, Washington, United States.
Prevencio is a funded company, having raised a total of $5.68M across 2 funding rounds to date. The company's 1st funding round was a Series B of $5M, raised on Jun 2015.
Founded in 2006 in Kirkland, United States, Prevencio operates in the biotechnology sector focused on cardiovascular health. Protein-based diagnostics and prognostic solutions are developed for diseases such as coronary artery disease. The HART assay, utilizing proteomics, is employed to diagnose coronary artery disease. Risks of myocardial infarction, stroke, or cardiovascular death within one year are assessed for diagnosed patients through protein signatures.
Prevencio's top competitors include SpectraWAVE, Boston Heart Diagnostics and Proxim Diagnostics.
Prevencio offers HART Tests.
Prevencio operates through Prevencio Inc..